

Cooperation agreement for Migraine Forum 2026/2027

Between

Teva Denmark A/S
Vandtårnsvej 3A
2860 Søborg, Denmark
CVR: 29 63 40 76

and

Lundbeck Pharma A/S
Ottiliavej 9
2500 Valby, Denmark
CVR: 56 75 02 15

and

AbbVie A/S
Titangade 11
2200 Copenhagen NE Denmark
CVR.: 34 46 28 28

and

The Danish Patient Association for Headache Sufferers
Sdr. Stationsvej 28A th
4200 Slagelse
CVR: 33 65 37 86

and

The Danish Headache Association
Mosevangen 49
3460 Birkerød
CVR.: 25 27 79 10

and

Danish Headache Society (DHOS)
Kristianiagade 12,
2100 Copenhagen Ø
CVR: 19 92 66 48

TABLE OF CONTENTS

1 The cooperation agreement.....3
2 Publication4
3 Personal data.....4
4 Changes5
5 Entry into force and termination5

This cooperation agreement (hereinafter referred to as the "Agreement") has been entered into between the above pharma companies, the Danish Headache Society and patient associations collectively referred to as the "Parties" and separately referred to as the "Party"

1 The cooperation agreement

1.1 The purpose of the collaboration is to focus on the fact that migraine constitutes the largest disease burden among 15 to 49-year-olds worldwide. It is estimated by the Danish Health Authority that approximately 640,000 Danes experience migraine, i.e. more than 1 in 10. Migraine costs Danish society 3.8 million extra sick days and DKK 1.2 billion in lost production annually. Migraine is a debilitating disease that affects the lives of the people living with the disease, either themselves or as relatives. Migraine is an overlooked disease and patients experience a long, stigmatized and problematic course of treatment through old treatment options and long waiting lists. Against this background, AbbVie, Teva and Lundbeck have entered into a collaboration in the Migraine Forum, which includes the two patient associations within headache and migraine, to work specifically on these issues. LEAD Agency is engaged to plan and carry out the task. The collaboration started in May 2023, but this agreement specifically includes the collaboration in 2026/2027, see section 1.2. The Danish Headache Society (DHOS) will enter into the collaboration in 2026/2027 specifically and solely with a view to professional contribution to section 1.2 and section 1.3.

1.2 The project scope in 2026/2027 is a sharpened focus on treatment pathways, disease burden, sick leave, lost work production, etc. in migraine. A special focus on migraine as a predominantly women's disease that creates gender inequality by pulling many women out of the workforce, including in welfare professions. Highlight the derived effects of a targeted investment in better treatment of migraine, including strengthened gender equality in access to the labour market. No medical or other products are discussed.

The cooperation in this agreement consists of one or more meetings where the Parties meet (physically and/or online) The forward-looking efforts, following the meeting at Christiansborg the 18/2-2026(as described in the agreement between Teva Denmark A/S, Lundbeck Pharma A/S, AbbVie A/S, Pfizer ApS, The Danish Patient Association for Headache Sufferers, The Headache Association and Danish Headache Society (DHOS), dated 17/10-2025 , covering the collaboration 2025/2026), have a regional and national focus and will, among other things, support dialogue on how migraine can be included as a relevant example in connection with the development of strategies, plans and initiatives in the primary health care system.

The 2026/2027 activities carried out under this cooperation agreement may include, among other things: (i) joint kick-off and strategic start-up, (ii) preparation of two short policy notes, including a regional memorandum and a national memorandum, (iii) dialogue with selected health councils, regions and/or regional council chairs, (iv) dialogue with national health spokespersons and relevant decision-makers, (v) preparation, implementation and follow-up of selected meetings, (vi) debriefing, summarising and assessing relevant follow-up options, and (vii) any clarification of the framework for an academic task force or other phase 2 activity.

The specific activities, deliverables, schedules and priorities are determined on an ongoing basis by the continuing Parties within the framework of this agreement and relevant approved project material.

If material changes occur in activities, deliverables, budget or participating parties, such changes must be agreed in writing between the relevant Parties.

1.3 The meetings are held ad hoc according to common agreement and need. The invitation and preliminary agenda will be sent to the meeting participants approximately 14 days before the meeting.

Participants and short minutes of the meetings will be sent to the participants after the meeting. The patient associations and DHOS are part of the collaboration as experts in migraine and thus contribute with professionalism, knowledge and guidance to ensure the right content and agenda for developed material and consultation.

- 1.4 Roles and responsibilities: The pharma companies (the "Companies") facilitate the meetings and cover the payments to LEAD Agency, CVR. nr. 30803965, Ravnsborg Tværgade 5C, 1. Sal, 2200 København N, Danmark. The companies share any expenses in this connection between themselves. The activities and content of the Migraine Forum are developed and executed by LEAD Agency and jointly discussed by all partners involved. Only LEAD Agency is paid.
- 1.5 In addition, there are no financial arrangements between the Parties in relation to this agreement.
- 1.6 All Companies commit to ensure that any activity under the agreement complies with applicable legislation and the rules of the Danish Association of the Pharmaceutical Industry's Code of Conduct for Advertising (= "ENLI Code"). The Parties represent and warrant that they comply with and undertake in the performance of their obligations under this Agreement to comply with, all applicable laws and regulations, including applicable anti-corruption laws and the rules of the ENLI Code. All Companies warrant that it, to the best of their knowledge, do not and will not engage any person or entity to perform services under this agreement who was convicted for any criminal offense, e.g. payment of illegal gratuities, fraud, false statement, blackmail, falsification or destruction of records. All matters regarding the meetings must at all times comply with applicable legislation and the Danish Association of the Pharmaceutical Industry's Code of Conduct for Advertising (= "ENLI Code").
- 1.7 All Companies agree to treat as confidential all non-public information exchanged or obtained in connection with the activities hereunder and its organization. Such information shall not be disclosed to any third party without the prior written consent of the disclosing party, except as required by law or regulation. All parties shall ensure that their respective representatives are aware of and comply with this obligation.
- 1.8 All Companies acknowledge and agree that all activities under the agreement shall be conducted in strict compliance with applicable E.U. and Danish competition laws. All Companies shall not discuss, coordinate, or exchange any competitively sensitive information, including but not limited to pricing, markets, customers, sales strategies, future plans, or any information that could restrict fair competition. No agreements, arrangements, or understandings that could unlawfully restrain trade or limit competition shall be entered into during the course any activity under this agreement or its planning. Neither Company may exchange information that may be or is distorting competition. If a violation of this provision is suspected, all relevant all Companies shall immediately take steps to prevent the violation.

2 Publication

- 2.1 The companies must publish the Agreement on their respective websites in connection with the publication of their collaborations with patient associations (cf. ENLI Code)
- 2.2 The patient associations must publish the agreement on their websites. (cf. ENLI Code)

3 Personal data

- 3.1 In carrying out this task, the parties must act in accordance with all relevant personal data legislation

4 Changes

Amendments and additions to this Agreement must, in order to be binding, be in writing and duly signed by the Parties.

5 Entry into force and termination

The Agreement enters into force on 01.07.2026 and expires automatically on 30.06.2027, unless it is extended by several of the Parties.

A Party may choose to withdraw from the Agreement with immediate notice without consequence for the other Parties.

Date: 11.07, 2026

20-jul-2026

17-Jul-2026

Teva Denmark A/S:

DocuSigned by:

Bjarne Nemi

1ACD4A3C33314DD...

Name: Morten Nielsen

Title: General Manager & Bjarne Niemi

Titel: Sr Manager Business Controller, Scandinavia

DocuSigned by:

Morten Nelsen

64E67C6A565E463...

Date: 11.07, 2026

03-Aug-2026

AbbVie:

Signed by:

Thea Larsen

6DE487BFA6704D4...

Name: Thea Larsen

Title: Country Manager

Date: 11.07, 2026

17-Jul-2026

Lundbeck Pharma A/S

Signed by:

Søren Klein Kristensen

531F3D53CA904F2...

Name: Søren Klein Kristensen

Title: Senior Vice President,

Region NCE & Partner Markets

Date: 11.07, 2026

06-aug-2026

The Danish Patient Association for
Headache Sufferers

Signed by:

Christian Hansen

680DBE759737454...

Name: Christian Hansen


Title: Chairman

Date: 11.07, 2026

18-jul-2026

The Headache Association

Signed by:



21Aafb6fA24347E...

Name: Anne Egelund


Title: Chairman

Date: 11.07, 2026

27-jul-2026

Danish Headache Society

Signed by:



24B61E58F7554BA...

Name: Dagmar Beier

Title: Chairman